A receptionist works at the Otsuka Holdings Co headquarters in Tokyo December 15, 2010. REUTERS/Toru Hanai (Reuters) - Japanese drugmaker Otsuka Holdings Co Ltd plans to buy U.S.-based Avanir ...
ANN ARBOR, Mich., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that Otsuka Pharmaceutical Co., Ltd. (Otsuka) has submitted a New Drug Application (NDA) to the Japanese ...
TOKYO (Reuters) - Japan's Otsuka Holdings <4578.T> priced its $2.4 billion initial public offering at the lower end of its range, reflecting worries the drugmaker will struggle to find a successor for ...
– Third Largest Global Market for Cardiovascular Prevention Represents Significant Global Growth Opportunity for NEXLETOL – ...
ARIAD to receive upfront payment of USD 77.5 million and subsequent milestone-based payments Otsuka to obtain rights in ten Asian countries to Iclusig, a newest-generation treatment for patients with ...
Japan's Otsuka Pharmaceuticals accused the U.S. FDA in a unique court suit of manipulating its regulatory procedures to kill off its 7-year exclusivity to market Abilify (aripiprazole) for treating ...
Tokyo-based Otsuka Pharmaceutical scrapped two licensing deals with ophthalmic biotech Acucela following disappointing Phase III results for the venture's lead candidate, ACU-4429 (emixustat), which ...
TOKYO (Reuters) -Japan's Otsuka Pharmaceutical said on Thursday it agreed to pay more than $1 billion to acquire Jnana Therapeutics as it looks to expand its drug pipeline and research base in the ...
TipRanks on MSN
Esperion partner Otsuka launches NEXLETOL in Japan
Esperion (ESPR) announced that Otsuka Pharmaceutical, the Company’s partner in Japan for the development and commercialization of NEXLETOL ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback